Skip to content

Opening book details…

Can I read Metformin coordinates with mesenchymal cells to promote VEGF-mediated angiogenesis in diabetic wound healing through Akt/mTOR activation on EtoBox?

Metformin coordinates with mesenchymal cells to promote VEGF-mediated angiogenesis in diabetic wound healing through Akt/mTOR activation by Fangzhou Du; Mengmeng Liu; Jingwen Wang; Lvzhong Hu; Dongao Zeng; Shaocong Zhou; Lixing Zhang; Meijia Wang; Xi Xu; Chenglong Li; Jingzhong Zhang; Shuang Yu is a Medicine article available to read on EtoBox.

What is Metformin coordinates with mesenchymal cells to promote VEGF-mediated angiogenesis in diabetic wound healing through Akt/mTOR activation about?

Introduction Cell therapy with mesenchymal stem cells (MSCs) and biomaterials holds great potential for the treatment of diabetic ulceration; however, the underlying mechanism as well as its compatibility with the first-line anti-diabetic drug, metformin (MTF), has not been well elucidated. Methods MSCs derived from the umbilical cord were labeled with fluorescent proteins, followed by transplantation in a fibrin scaffold (MSCs/FG) onto the STZ-induced diabetic wound in a C57BL6/J mouse model. MTF was administered by oral gavage at a dose of 250 mg/kg/day. The wound healing rate, epithelization, angiogenesis, and underlying mechanism were evaluated in MSCs/FG- and MTF-treated diabetic wounds. Moreover, the dose-dependent effects of MTF and involvement of the Akt/mTOR pathway were analyzed in keratinocyte and fibroblast cultures. Results MSCs/FG significantly promoted angiogenesis in diabetic wound healing without signs of differentiation or integration. The recruitment of fibroblasts and keratinocytes by MSCs/FG promotes migration and vascular endothelial growth factor (VEGF) expression in an Akt/mTOR-dependent manner. MTF, which is generally considered a mTOR inhibitor, displayed

Who reads Metformin coordinates with mesenchymal cells to promote VEGF-mediated angiogenesis in diabetic wound healing through Akt/mTOR activation?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Fangzhou Du; Mengmeng Liu; Jingwen Wang; Lvzhong Hu; Dongao Zeng; Shaocong Zhou; Lixing Zhang; Meijia Wang; Xi Xu; Chenglong Li; Jingzhong Zhang; Shuang Yu
Publisher
Elsevier BV
Published
2023
Language
EN
Field
Medicine (Health Sciences)

More by Fangzhou Du; Mengmeng Liu; Jingwen Wang; Lvzhong Hu; Dongao Zeng; Shaocong Zhou; Lixing Zhang; Meijia Wang; Xi Xu; Chenglong Li; Jingzhong Zhang; Shuang Yu

Browse all works by Fangzhou Du; Mengmeng Liu; Jingwen Wang; Lvzhong Hu; Dongao Zeng; Shaocong Zhou; Lixing Zhang; Meijia Wang; Xi Xu; Chenglong Li; Jingzhong Zhang; Shuang Yu